2 results
Approved WMOCompleted
Primary: To characterize the safety and tolerability of LXH254 single agent and to identify recommended doses for future studies in adult patients with advanced solid tumors harboring MAPK pathway alterations.To characterize the safety and…
Approved WMOCompleted
Primary Objective: To assess the sensitivity and specificity of rhPSMA-7.3 (18F) PET in detecting N1 disease on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND. At least one positive pelvic LN on…